Mitch A Phelps
Overview
Explore the profile of Mitch A Phelps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
2401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hill K, Abbott N, Na J, Rudek M, Moore K, Lee E, et al.
J Pharm Biomed Anal
. 2024 Oct;
253():116531.
PMID: 39454543
An isotope-dilution bioanalytical assay for abemaciclib and its metabolites in combination with olaparib was developed and validated in human plasma K2 EDTA. For the quantitative assay, human plasma samples (or...
2.
Elgamal O, Fobare S, Vibhute S, Mehmood A, Vroom D, Johnson M, et al.
JCI Insight
. 2024 Apr;
9(8).
PMID: 38646934
Acute myeloid leukemia (AML) is a fatal disease characterized by the accumulation of undifferentiated myeloblasts, and agents that promote differentiation have been effective in this disease but are not curative....
3.
Bello K, Lorch G, Papich M, Kim K, Toribio R, Yan L, et al.
J Vet Pharmacol Ther
. 2024 Feb;
47(4):280-287.
PMID: 38334367
Additional immunomodulatory treatment is needed for the management of immune-mediated disease in horses. Mycophenolate mofetil (MMF) is an immunomodulatory agent used in human and veterinary medicine for the prevention of...
4.
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, et al.
Breast Cancer Res Treat
. 2024 Jan;
205(1):61-73.
PMID: 38280052
Purpose: Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a...
5.
Seligson N, Zhang X, Zemanek M, Johnson J, VanGundy Z, Wang D, et al.
Front Pharmacol
. 2024 Jan;
14:1334440.
PMID: 38259277
Polymorphisms in genes responsible for the metabolism and transport of tacrolimus have been demonstrated to influence clinical outcomes for patients following allogeneic hematologic stem cell transplant (allo-HSCT). However, the clinical...
6.
and Evaluation of the Pathology and Safety Aspects of Three- and Four-Way Junction RNA Nanoparticles
Jin K, Liao Y, Cheng T, Li X, Lee W, Pi F, et al.
Mol Pharm
. 2024 Jan;
21(2):718-728.
PMID: 38214504
RNA therapeutics has advanced into the third milestone in pharmaceutical drug development, following chemical and protein therapeutics. RNA itself can serve as therapeutics, carriers, regulators, or substrates in drug development....
7.
Li X, Jin K, Cheng T, Liao Y, Lee W, Bhullar A, et al.
Biomaterials
. 2024 Jan;
305:122432.
PMID: 38176263
The field of RNA therapeutics has been emerging as the third milestone in pharmaceutical drug development. RNA nanoparticles have displayed motile and deformable properties to allow for high tumor accumulation...
8.
Williams N, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, et al.
Ther Adv Med Oncol
. 2023 Dec;
15:17588359231217976.
PMID: 38152697
Background: Heat shock protein 90 (HSP90) is a molecular chaperone required for stabilization of client proteins over-activated in triple-negative breast cancer (TNBC). Over-expression of HSP90 client proteins has been implicated...
9.
Vu T, Kim K, Manna M, Thomas J, Remaily B, Montgomery E, et al.
Pharmacol Res
. 2023 Dec;
199:107048.
PMID: 38145833
High baseline clearance of immune checkpoint inhibitors (ICIs), independent of dose or systemic exposure, is associated with cachexia and poor outcomes in cancer patients. Mechanisms linking ICI clearance, cachexia and...
10.
Guo Y, Remaily B, Thomas J, Kim K, Kulp S, Mace T, et al.
Clin Cancer Res
. 2023 Nov;
30(5):942-958.
PMID: 37921739
Immune-checkpoint inhibitor (ICI) therapy has dramatically changed the clinical landscape for several cancers, and ICI use continues to expand across many cancer types. Low baseline clearance (CL) and/or a large...